Compare Medtronic PLC (MDT) vs Rivian Automotive, Inc. (RIVN) Price & Performance

Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.

The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.

Rivian Automotive (RIVN) trades at $17.19, down 1.52% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company continues to post significant losses, with a net income margin of -63.62% for 2025, though revenue growth has been steady and recent quarterly EPS have beaten expectations. Cash flow remains negative, but the trend shows improvement from prior years. Analyst sentiment is mixed with a consensus price target of $19.22.

The outlook hinges on successful execution of the R2 vehicle launch and path to profitability. Investment opportunity lies in the potential for market share gains in the EV sector, but risks include high cash burn, competitive pressures, and reliance on capital markets for funding. The stock's performance will be closely tied to quarterly earnings and production updates.